|
Solvonis Therapeutics PLC on Monday said the US Patent & Trademark Office has allowed a core patent application covering compounds in its artificial-intelligence-enabled central-nervous-system discovery programme, granting protection in the US’s drug market for at least 18 years. The application, titled ‘bridged ring compounds and their therapeutic use as CNS agents’, received a first-action allowance with no objections or rejections, Solvonis said. Allowance means the patent will be issued once administrative formalities are complete, expected in the coming months. The London-based biotechnology company, which focuses on developing therapeutics for mental health and substance use disorders, said the patent secures rights to both the composition and therapeutic use of a group of morpholine-class compounds. These molecules were originally developed by Awakn Life Sciences Corp and now form a core part of Solvonis’s proprietary central nervous system compound library. Chief Scientific Officer David Nutt said the decision ‘strengthens the foundation of our discovery platform and provides long-term protection for a chemically distinct series of CNS-active compounds already integrated into our AI-supported programme’. Chief Executive Anthony Tennyson added that the favourable outcome ‘validates the early-stage innovation acquired through Awakn and enhances the strategic value of our AI-enabled platform’. Shares in Solvonis were up 2.2% at 0.18 pence in London on Monday morning. Copyright 2025 Alliance News Ltd. All Rights Reserved.
|
